Immunotherapy and PARP inhibitor combo tested in Hard-to-Treat breast cancer
NCT ID NCT03025035
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the PARP inhibitor olaparib (Lynparza) can shrink tumors in people with advanced BRCA-mutated breast cancer. Fourteen participants whose cancer had progressed after prior treatments were enrolled. The main goal was to see how many patients responded to the combination, with tumor assessments every 9 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and olaparib (Lynparza)
What this could lead to
If this combination works well, it could offer a new treatment option for people with advanced BRCA-mutated breast cancer that has stopped responding to other therapies.
What could go wrong
This is a very small, early-phase pilot study with only 14 participants, so results may not apply to everyone. The cancer is incurable, and the combination may cause significant side effects from both immunotherapy and the PARP inhibitor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States